Myriad Genetics MYGN Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
- Myriad Genetics (MYGN) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $13.38 in Q1 2026.
- How has Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
- Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price decreased by 0.0% year-over-year, from $13.38 to $13.38.
- What is the long-term trend for Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
- Over 5 years (2020 to 2025), Myriad Genetics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a -10.5% compound annual growth rate (CAGR), from $23.24 to $13.38.